ATLAS fair value
ATLAS has no fair value for this stock today.
Vogenx stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 27, 2026 · USD
ATLAS has no fair value for this stock today.
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Vogenx a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $16.58 and $21.82; in 9 out of 10, between $13.00 and $27.84. Estimated annual volatility is 76%.
ATLAS does not publish a fair value for VOGX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks VOGX has traded between $12.95 and $38.41. Today it is 49.4% below that high and 50% above its low.
Its beta is 0.00: it tends to move less than the market.
Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions.
Want to see everything about Vogenx?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions.
46%: close to a coin flip. In half of the simulated outcomes, VOGX ends the month between $16.58 and $21.82.
Vogenx's market capitalization is $271M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 76%. In a typical month, half of the outcomes end between $16.58 and $21.82.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy